China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 10 Apr, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- Artemis II On Track for Friday Evening Splashdown Off San Diego
- Anthropic May Build Its Own AI Chips Amid Shortages
- China Logs First Producer Inflation in Over 3 Years
- Chinese Startup Raises $293 Million to Tackle AGI with World Model
- Trump Pressures NATO to Participate in Hormuz Opening Says Rutte
- Hunter Biden Challenges Trump's Sons to Cage Match
- US PCE Inflation Picked up in February on Solid Consumer Spending
- SpaceX Lost $5 Billion in 2025
- Federal Judge Orders Pentagon to Ditch Onerous Press Restrictions—Again
- Melania Denies She Met Donald Through Epstein